Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma

References

• Ozturk N, Ozturk D, Kavakli IH, Okyar A. Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy. Int J Mol Sci. 2017;18:10.
   Web of Science ®Google Scholar
• Lévi F, Altinok A, Clairambault J, Goldbeter A. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans a Math Phys Eng Sci. 2008;366(1880):3575–3598.
   PubMed Web of Science ®Google Scholar
• Lévi F, Komarzynski S, Huang Q, et al. Tele-monitoring of cancer patients’ rhythms during daily life identifies actionable determinants of circadian and sleep disruption. Cancers (Basel). 2020;12(7):1–21.
   Web of Science ®Google Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000.
   PubMedGoogle Scholar
• Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012;131(11):2684–2692.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Komarzynski S, Palesh OG, et al. Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. Cancer Med. 2018;7(9):4396–4405.
   PubMed Web of Science ®Google Scholar
• Lévi F, Dugué PA, Innominato P, et al. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 2014;31(8):891–900.
   PubMed Web of Science ®Google Scholar
• Ortiz-Tudela E, Innominato PF, Rol MA, Lévi F, Madrid JA. Relevance of internal time and circadian robustness for cancer patients. BMC Cancer. 2016;16:1.
   Web of Science ®Google Scholar
• Soták M, Polidarová L, Ergang P, Sumová A, Pácha J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 2013;132(5):1032–1041.
   PubMed Web of Science ®Google Scholar
• Huisman SA, Oklejewicz M, Ahmadi AR, et al. Colorectal liver metastases with a disrupted circadian rhythm phase shift the peripheral clock in liver and kidney. Int J Cancer. 2015;136(5):1024–1032.
   PubMed Web of Science ®Google Scholar
• Masri S, Papagiannakopoulos T, Kinouchi K, et al. Lung adenocarcinoma distally rewires hepatic circadian homeostasis. Cell. 2016;165(4):896–909.
   PubMed Web of Science ®Google Scholar
• Hojo H, Enya S, Arai M, et al. Remote reprogramming of hepatic circadian transcriptome by breast cancer. Oncotarget. 2017;8(21):34128–34140.
   PubMedGoogle Scholar
• Granda TG, Liu X-H, Smaaland R, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J. 2005;19(2):304–306.
   PubMedGoogle Scholar
• Wood PA, Du-Quiton J, You S, Hrushesky WJM Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.
   Google Scholar
• Li XM, Tanaka K, Sun J, et al. Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin. Br J Cancer. 2005;92(9):1684–1689.
   PubMed Web of Science ®Google Scholar
• Granda TG, D’Attino RM, Filipski E, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer. 2002;86(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Sothern RB, Lévi F, Haus E, Halberg F, Hrushesk WJM. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989;81(2):135–145.
   PubMedGoogle Scholar
• Chakarov S, Petkova R, Russev G, Zhelev N. DNA damage and the circadian clock. Biodiscovery. 2014;13(13):1.
   Google Scholar
• Seto Y, Okazaki F, Horikawa K, Zhang J, Sasaki H, To H. Influence of dosing times on cisplatin-induced peripheral neuropathy in rats. BMC Cancer. 2016;16:1.
   Web of Science ®Google Scholar
• Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020;127.
   PubMed Web of Science ®Google Scholar
• Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res. 2012;4.
   PubMedGoogle Scholar
• Cristea M, Han E, Salmon L, Morgan RJ. Review: practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol. 2010;2.
   PubMedGoogle Scholar
• Boussios S, Pavlidis N. Ovarian cancer: state of the art and perspectives of clinical research. Ann Transl Med. 2020;8:24.
   PubMed Web of Science ®Google Scholar
• Bespalov VG, Kireeva GS, Belyaeva OA, et al. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model. J Surg Oncol. 2016;113(4):438–442.
   PubMed Web of Science ®Google Scholar
• Kireeva G, Kruglov S, Maydin M, et al. Modeling of Chemoperfusion vs Intravenous Administration of Cisplatin in Wistar Rats. Adsorpt Tissue Distribution Mol. 2020;25(20):4733.
   Google Scholar
• Redon CE, Dickey JS, Nakamura AJ, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci U S A. 2010;107(42):17992–17997.
   PubMed Web of Science ®Google Scholar
• Gubareva EA, Maydin MA, Tyndyk ML, Vìnogradova IA, Panchenko AV. Circadian rhythm of proliferation in intestinal epithelium and mammary tumors in HER-2/neu transgenic and FVB/N wild type mice; their correction with melatonin. Vopr Onkol. 2019;65(1):154–158.
   Google Scholar
• Reyna JC, Barbeito CG, Badrán AF, Moreno FR. [Mitotic activity of duodenal-crypt enterocytes in mice with hepatocarcinoma]. Medicina (B Aires). 1997;57(6):708–712.
   PubMed Web of Science ®Google Scholar
• Turinetto V, Giachino C, Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions. Nucleic Acids Research. 2015;5(43): 2489–2498.
   Google Scholar
• Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29:5.
   Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D. 2020;20.
   PubMed Web of Science ®Google Scholar
• Shostak A. Circadian clock, cell division, and cancer: from molecules to organism. Int J Mol Sci. 2017;18:4.
   Web of Science ®Google Scholar
• Palombo P, Moreno-Villanueva M, Mangerich A. Day and night variations in the repair of ionizing-radiation-induced DNA damage in mouse splenocytes. DNA Repair (Amst). 2015;28:37–47.
   PubMed Web of Science ®Google Scholar
• Yang Y, Adebali O, Wu G, et al. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. Proc Natl Acad Sci U S A. 2018;115(21):E4777–85.
   PubMed Web of Science ®Google Scholar
• Kang T-H, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A. 2010;107(11):4890–4895.
   PubMed Web of Science ®Google Scholar
• de Assis L, Moraes M, Magalhães-Marques K, Kinker G, Da Silveira Cruz-machado S, de Lauro Castrucci A. Non-metastatic cutaneous melanoma induces chronodisruption in central and peripheral circadian clocks. Int J Mol Sci. 2018;19(4):1065.
   PubMed Web of Science ®Google Scholar
• Yang K, Ye H, Tan X-M, Fu X-J, Li H-X. Daily rhythm variations of the clock gene PER1 and cancer-related genes during various stages of carcinogenesis in a golden hamster model of buccal mucosa carcinoma. Onco Targets Ther. 2015;1419.
   PubMed Web of Science ®Google Scholar
• Tan X-M, Ye H, Yang K, et al. Circadian variations of clock gene Per2 and cell cycle genes in different stages of carcinogenesis in golden hamster buccal mucosa. Sci Rep. 2015;5(1):9997.
   PubMedGoogle Scholar
• Pelz JOW, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162.
   PubMed Web of Science ®Google Scholar
• Dakup PP, Porter KI, Little AA, et al. The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models. Oncotarget. 2018;9(18):14524–14538.
   PubMedGoogle Scholar
• Levi FA, Hrushesky WJM, Blomquist CH, et al. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982;42:3.
   Web of Science ®Google Scholar
• Boughattas NA, Lévi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res. 1989;49(12):3362–3368.
   PubMed Web of Science ®Google Scholar
• Boughattas NA, Lévi F, Hecquet B, et al. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol. 1988;96(2):233–247.
   PubMed Web of Science ®Google Scholar